Technical analysis of Kezar Life Sciences, Inc. (KZR): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor.
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +15.90% |
| 1 year | +94.92% |
| 3 years | -94.02% |
| 5 years | -99.25% |
52-Week Range
| 52-week High | $7.55 |
| 52-week Low | $3.53 |
| Avg Volume (90d) | 72K |
Technical Indicators
| SMA 50 | $7.13 |
| SMA 200 | $5.81 |
| Beta | 0.43 |
| 30-day Volatility (annualised) | 53.1% |
| Price vs SMA 50 | +2.3% |
| Price vs SMA 200 | +25.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $6.21 | |
| 2025-11 | $6.20 | -0.2% |
| 2025-12 | $6.29 | +1.5% |
| 2026-01 | $6.07 | -3.5% |
| 2026-02 | $6.70 | +10.4% |
| 2026-03 | $7.42 | +10.7% |
| 2026-04 | $7.31 | -1.5% |
| 2026-05 | $7.29 | -0.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | $0.10 | $672M |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
Price
| Price | $7.29 |
| Market Cap | $54M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.82 |
| EV / EBITDA | 0.46 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 24.46 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -5.93 |